MDM2 expression and regulation in prostate cancer racial disparity

International Journal of Clinical and Experimental Pathology

Volumn 2, Issue 4, 2009, Pages 353-360

  Wang, Guimin ^a   Firoz, Elnaz F ^a   Rose, Amy ^a   Blochin, Elen ^a   Christos, Paul ^b   Pollens, Danuta ^a   Mazumdar, Madhu ^b   Gerald, William ^c   Oddoux, Carole ^a   Lee, Peng ^a   Osman, Iman ^a  

^a NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b NEW YORK PRESBYTERIAN HOSPITAL   (United States)

^c MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

MDM2; Prostate cancer; Single nucleotide polymorphism; SNP309

Indexed keywords

EID: 67149141477     PISSN: None     EISSN: 19362625     Source Type: Journal    
DOI: None     Document Type: Article

References (29)

1. Pietsch EC, Humbey O and Murphy ME. Polymorphisms in the p53 pathway. Oncogene 2006;25:1602-1611.
2. Haupt Y, Maya R, Kazaz A and Oren M. Mdm2 promotes the rapid degradation of p53. Nature 1997;387:296-299.
3. Kubbutat MH, Jones SN and Vousden KH. Regulation of p53 stability by Mdm2. Nature 1997;387:299-303.
4. Bond GL, Hu W and Levine AJ. MDM2 is a central node in the p53 pathway: 12 years and counting. Curr Cancer Drug Targets 2005;5:3-8.
5. Osman I, Sherman E, Singh B, Venkatraman E, Zelefsky M, Bosl G, Scher H, Shah J, Shaha A, Kraus D, Cordon-Cardo C and Pfister DG. Alteration of p53 pathway in squamous cell carcinoma of the head and neck: impact on treatment outcome in patients treated with larynx preservation intent. J Clin Oncol 2002; 20:2980-2987.
6. Agus DB, Cordon-Cardo C, Fox W, Drobnjak M, Koff A, Golde DW and Scher HI. Prostate cancer cell cycle regulators: response to androgen withdrawal and development of androgen independence. J Natl Cancer Inst 1999;21:1869-1876.
7. Osman I, Drobnjak M, Fazzari M, Ferrara J, Scher HI and Cordon-Cardo C. Inactivation of the p53 pathway in prostate cancer: impact on tumor progression. Clin Cancer Res 1999;5: 2082-2088.
8. Leite KR, Franco MF, Srougi M, Nesrallah A, Bevilacqua RG, Darini E, Carvalho CM, Meirelles MI, Santana I and Camara-Lopes LH. Abnormal expression of MDM2 in prostate carcinoma. Mod Pathol 2001;5:428-436.
9. Khor LY, Desilvio M, Al-Saleem T, Hammond ME, Grignon DJ, Sause W, Pilepich M, Okunieff P, Sandler H, Pollack A; Radiation Therapy Oncology Group. MDM2 as a predictor of prostate carcinoma outcome: an analysis of Radiation Therapy Oncology Group Protocol 8610. Cancer 2005;104:962-967.
10. Bianco R, Caputo R, Caputo R, Damiano V, De Placido S, Ficorella C, Agrawal S, Bianco AR, Ciardiello F and Tortora G. Combined targeting of epidermal growth factor receptor and MDM2 by gefitinib and antisense MDM2 cooperatively inhibit hormone-independent prostate cancer. Clin Cancer Res 2004;10:4858-4864.
11. Wang H, Yu D, Agrawal S and Zhang. Experimental therapy of human prostate cancer by inhibiting MDM2 expression with novel mixed-backbone antisense oligonucleotides: in vitro and in vivo activities and mechanisms. Prostate 2003;54:194-205.
12. Zhang Z, Li M, Wang H, Agrawal S and Zhang R. Antisense therapy targeting MDM2 oncogene in prostate cancer: Effects on proliferation, apoptosis, multiple gene expression, and chemotherapy. Proc Natl Acad Sci USA 2003; 100:11636-11641.
13. Bond GL, Hu W, Bond EE, Robins H, Lutzker SG, Arva NC, Bargonetti J, Bartel F, Taubert H, Wuerl P, Onel K, Yip L, Hwang SJ, Strong LC, Lozano G and Levine AJ. A single nucleotide polymorphism in the MDM2 promoter attenuates the p53 tumor suppressor pathway and accelerates tumor formation in humans. Cell 2004;119:591-602.
14. Yuan H, Gong A and Young CY. Involvement of transcription factor Sp1 in quercetin-mediated inhibitory effect on the androgen receptor in human prostate cancer cells. Carcinogenesis 2005;26:793-801.
15. Saville B, Wormke M, Wang F, Nguyen T, Enmark E, Kuiper G, Gustafsson JA and Safe S. Ligand-, cell-, and estrogen receptor subtype (alpha/ beta)-dependent activation at GC-rich (Sp1) promoter elements. J Biol Chem 2000; 275:5379-5387.
16. Bartel F, Jung J, Bohnke A, Gradhand E, Zeng K, Thomssen C and Hauptmann S. Both germ line and somatic genetics of the p53 pathway affect ovarian cancer incidence and survival. Clin Cancer Res 2008;14:89-96.
17. Bond GL, Hirshfield KM, Kirchhoff T, Alexe G, Dond EE, Robbins H, Bartel F, Taubert H, Wuerl P, Hait W, Toppmeyer D, Offit K and Levine AJ. MDM2 SNP309 accelerates tumor formation in a gender-specific and hormone-dependent manner. Cancer Res 2006;66:5104-5110.
18. Bond GL, Menin C, Bertorelle R, Alhopuro P, Aaltonen LA and Levine AJ. MDM SNP309 accelerates colorectal tumour formation in women J Med Genet 2006;43:950-952.
19. Lind H, Zienolddiny S, Ekstrom PO, Skaug V and Haugen A. Association of a functional polymorphism in the promoter of the MDM2 gene with risk of nonsmall cell lung cancer. Int J Cancer 2006;119:718-721.
20. Menin C, Scaini MC, De Salvo GL, Biscuola M, Quaggio M, Esposito G, Belluco C, Montagna M, Agata S, D'Andrea E, Nitti D, Amadori A and Bertorelle R. Association between MDM2-SNP309 and age at colorectal cancer diagnosis according to p53 mutation status. J Natl Cancer Inst 2006;98:285-288.
21. Alhopuro P, Ylisaukko-Oja SK, Koskinen WJ, Bono P, Arola J, Jarvinen HJ, Mecklin JP, Atula T, Kontio R, Makitie AA, Suominen S, Leivo I, Vahteristo P, Aaltonen LM and Aaltonen LA. The MDM2 promoter polymorphism SNP309T - >G and the risk of uterine leiomyosarcoma, colorectal cancer, and squamous cell carcinoma of the head and neck. J Med Genet 2005;42:694-698.
22. Yarden RI, Friedman E, Metsuyanim S, Olender T, Ben-Asher E and Papa MZ. MDM2 SNP309 accelerates breast and ovarian carcinogenesis in BRCA1 and BRCA2 carriers of Jewish-Ashkenazi descent. Breast Cancer Res Treat 2008;111:497-504.
23. Cookson M, Aus G, Burnett AL, Canby-Hagino Ed, D'Amico AV, Dmochowski RR, Eton DT, Forman JD Goldenberg SL, Hernandez J, Higano CS, Kraus SR, Moul JW, Tangen C, Thrasher JB and Thompson I. Variation in the definition of biochemical recurrence in patients treated for localized prostate cancer: The American Urological Association prostate guidelines for localized prostate cancer update panel report and recommendations for a standard in the reporting of surgical outcomes. J Urol 2007;177:540-545
24. Hammock L, Lewis M, Phillips C and Cohen C. Strong HER-2/neu protein overexpression by immunohistochemistry often does not predict oncogene amplification by fluorescence in situ hybridization. Hum Pathol 2003;34:1043-1047.
25. Stoehr R, Hitzenbichler F, Kneitz B, Hammerschmied CG, Burger M, Tannapfel A and Hartmann A. MDM2-SNP309 polymorphism in prostate cancer: no evidence for association with increased risk or histopathological tumor characteristics. Br J Cancer 2008;99:78-82.
26. Kibel A, Jin C, Klim A, Luly J, A Roehl K, Wu WS and Suarez BK. Association between polymorphisms in cell cycle genes and advanced prostate carcinoma. Prostate 2008; 68:1179-1186.
27. Pine S, Mechanic L, Bowman E, Welsh JA, Chanock SC, Shields PG and Harris CC. MDM2 SNP309 and SNP354 are not associated with lung cancer risk. Cancer Epidemiol Biomarkers Prev 2006;15:1559-1561.
28. Schlomm T, Iwers L, Kirstein P, Jessen B, Kollermann J, Minner S, Passow-Drolet A, Mirlacher M, Milde-Langosch K, Graefen M, Haese A Steuber T, Simon R, Huland H, Sauter G and Erbersdobler A. Clinical significance of p53 alterations in surgically treated prostate cancers. Mod Pathol 2008.
29. Langerød A, Zhao H, Borgan Ø, Nesland JM, Bukholm IR, Ikdahl T, Karesen R, Borresen-Dale AL and Jeffrey SS. TP53 mutation status and gene expression profiles are powerful prognostic markers of breast cancer. Breast Cancer Res 2007;9:R30.